AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01221142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cincinnati Sub-Zero, Blanketrol III
Study NCT00722215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123 (selective endothelin A receptor antagonist)
Description: Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.
Study NCT00722215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % saline
Description: Single 15ml 0.9% saline infused for 15 mins as placebo control
Study NCT00722215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Single dose of nifedipine 10 mg given orally as active control
Study NCT05060679 — intervention group
Intervention type: OTHER
Intervention: Supportive therapy at the ICU
Description: Non-septic ICU patients received adequate supportive treatment (fluid resuscitation, respiratory, anticoagulation, antimicrobial and vasopressor therapy along with sedation, ulcer prophylaxis and nutrition. Blood sampling for non-septic patients were the first (T1) and third (T3) postoperative morning at the ICU. Besides, 23 healthy outpatients were documented without sepsis or sepsis-related organ dysfuntion as a control group.
Study NCT05060679 — intervention group
Intervention type: OTHER
Intervention: Sepsis therapy
Description: Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis and nutrition. Blood samples were collected at the ICU from this patient group at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
Study NCT05060679 — intervention group
Intervention type: OTHER
Intervention: Sepsis-related organ dysfunction therapy
Description: Patient management of sepsis and sepsis-related organ dysfunction followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis, nutrition and renal replacement therapy (if needed). In this patient group, blood sampling was performed at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
Study NCT03973424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple
Description: Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, use a simplified form of tracking only high-calorie, high-fat foods in the study smartphone app, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
Study NCT03973424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard
Description: Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, track calorie intake, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
Study NCT01290237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin hydrocloride
Description: see description of study arms
Study NCT02432118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: Undergo lumpectomy
Study NCT02432118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02432118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency-Guided Localization
Description: Undergo radiofrequency-guided localization
Study NCT00728637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Passport to Heart Health Program
Description: Participants in this group received personalized heart disease risk factor screening at the baseline study visit. They were taught lifestyle approaches to risk reduction based upon national heart disease prevention guidelines, including the Adult Treatment Panel (ATP) III recommendations for improving blood cholesterol levels with a TLC diet. Participants had regular contact with study staff and will receive individualized feedback throughout the study.
Study NCT00728637 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Educational Materials
Description: Participants in the control group received an educational brochure about heart health at the baseline study visit.
Study NCT01876511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK-3475 10 mg/kg every 14 days
Study NCT01603719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: new infant formula with prebiotics and beta-palmitate
Description: experimental infant formula as sole source of nutrition over first 12 weeks of life
Study NCT00276250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab
Description: Efalizumab was a medication approved for use in psoriasis which was being explored to determine efficacy with immunosuppression following organ transplantation. Efalizumab was administered subcutaneously on a weekly basis. Upon efalizumab being withdrawn from the US market, the protocol was amended to alter the immunosuppressive regimen to abatacept for the study participants.
Study NCT00276250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept is drug used to treat autoimmune diseases. Abatacept is administered intravenously, monthly, in weight-based doses and is given for as long as transplanted islets are functioning.
Study NCT02193269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Minocycline
Description: you will receive 200 mg as a single daily dose for 4 days
Study NCT02774954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change the Cycle
Description: See previous response
Study NCT00276250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept is a medication to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens. Belatacept is administered intravenously. The protocol for this study was amended to substitute belatacept for abatacept for all newly enrolling participants (current participants remained on abatacept).
Study NCT02796651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (40 μg)
Description: Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
Study NCT02774954 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Change the Cycle
Description: See previous response
Study NCT05655442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early APM
Description: early APM within 3 and 6 month knee pain symptoms
Study NCT05655442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: delayed APM
Description: delayed APM within 6 and 12 month knee pain symptoms
Study NCT01196988 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2321138A
Description: intramuscular injections
Study NCT01196988 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluarixTM
Description: intramuscular injections
Study NCT01757639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01196988 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine GSK2604409A
Description: intramuscular injections
Study NCT01320436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: 3 capsules (820 mg containig 500 mg curcumin each) twice daily.
Study NCT01320436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-aminosalicylic acid
Description: The dosage of 5ASA medication will be the maximum dosage given in this group of patients according to clinical guidelines (4gr' per os + topical 1gr mesalamine
Study NCT01320436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-aminosalicylic acid
Description: The dosage of 5ASA medication will be the maximum dosage given in this group of patients according to clinical guidelines (4gr' per os + topical 1gr mesalamine
Study NCT03578640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir, Grazoprevir 50-100Mg Oral Tablet
Description: Daily, fixed-dose combination of Elbasvir 50 mg and Grazoprevir 100 mg given in a single oral tablet for 8 weeks.
Study NCT02970708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EFG group
Description: 88 anisometropic amblyopia will be recruited to receive Eyetronix Flicker Glasses treatment.
Study NCT02970708 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching group
Description: 88 anisometropic amblyopia will be recruited to receive patching treatment.
Study NCT02064569 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GS010
Study NCT04680702 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sims Score
Description: Evaluation Of siMS Score As Amarker Of Metabolic Syndrome In Children With Simple Obesity
Study NCT04041999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Cognition Training Program
Description: Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment. Some examples of tasks are: the management of a medical prescription, expiration of a medication, understanding of the prescriptions made by the doctor, guidelines for taking medication (doses, schedules ...) and indications and contraindications, filling pill boxes, recall of controls doctors, medication control, prospective memory of medical management, etc.
Study NCT04041999 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Cognition Training Program
Description: Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment. Some examples of tasks are: the management of a medical prescription, expiration of a medication, understanding of the prescriptions made by the doctor, guidelines for taking medication (doses, schedules ...) and indications and contraindications, filling pill boxes, recall of controls doctors, medication control, prospective memory of medical management, etc.
Study NCT03322020 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cyberknife boost 18 Gy
Description: pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 18 Gy/3 fx
Study NCT03322020 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cyberknife boost 21 Gy
Description: pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 21 Gy/3 fx
Study NCT02427087 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Aerobic Training twice
Description: Supervised aerobic exercise program of 60 min/2 days/week at 60-85% of heart rate reserve for 24 weeks and healthy diet
Study NCT02427087 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Diet
Description: Diet group (21) Recommendation for healthy diet.
Study NCT03712124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNSA-001
Description: CNSA-001 Powder for Suspension
Study NCT03712124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Suspension
Study NCT02267980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Inhalation anesthetic agent
Study NCT02267980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Inhalation anesthetic agent
Study NCT02267980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intravenous anesthetic agent
Study NCT02267980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Isotonic solution for placebo group
Study NCT01316978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: A single 2 x 100 mg dose of an experimental Ibuprofen Fast Melt Orodispersible Tablet administered orally, with a 7-day washout between visits
Study NCT01757639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01316978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: A single 200 mg Nurofen Meltlets Orodispersible Tablet administered orally, with a 7-day washout between visits
Study NCT01316978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: A single 2 x 100 mg dose of Junior Strength Motrin Chewable Tablet administered orally, with a 7-day washout between visits
Study NCT01352507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Administered Orally
Study NCT03459131 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A with Digital Zone Optics™ contact lenses
Description: Silicone hydrogel spherical contact lenses with Digital Zone Optics™
Study NCT01352507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered Orally
Study NCT01352507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Administered Orally
Study NCT01352507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Administered Orally
Study NCT02476773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel plus GLA-AF
Study NCT03430999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calmangafodipir
Description: Single ascending doses of 2 μmol/kg, 5 μmol/kg, and 10 μmol/kg
Study NCT03459131 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lenses
Description: Silicone hydrogel spherical contact lenses
Study NCT03736746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: An investigator-led discussion about the participant's pain experience which is focused on the participant reporting of functional pain goals (FPGs)
Study NCT01488825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Therapy
Description: Therapeutically oriented style of yoga originated from Pancha Kosha philosophy of Vedanta was used throughout the trial. All the sessions emphasized on postures, breathing practices with the specific focus on relaxation, combination of chants and meditation. Once a week, Kunjal and Jalaneti (cleansing practices) were practiced in guidance of therapist. They all were instructed to eat light and rest on Kriya days.
Study NCT03514303 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spiriplex Allergenex Microassay
Description: A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.
Study NCT03838341 — intervention group
Intervention type: DEVICE
Intervention: AtriClip™ LAA Exclusion System
Description: The left atrial appendage is closed from the epicardial side of the heart. Operative access is totally thoracoscopic. The designed and dedicated clip - AtriClip® (AtriCure, Ohio, USA) is introduced to the left pleura through thoracoscopic port.
Study NCT03838341 — intervention group
Intervention type: DRUG
Intervention: Oral anticoagulation therapy
Description: Anticoagulation therapy discontinuation - according to the standard of care at the discretion of the Investigator.
Study NCT03776578 — intervention group
Intervention type: PROCEDURE
Intervention: swallow fuction and swallow training
Description: nasogastric tube dependence rate
Study NCT01886937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.
Study NCT01886937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
Study NCT03546647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Aqua Comfort Plus Toric
Description: Daily disposable soft toric contact lens
Study NCT03546647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Aqua Comfort Plus Sphere
Description: Daily disposable soft spherical contact lens
Study NCT04372134 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation therapy
Description: A sham-controlled double-blind randomized study was undertaken. 28 patients with chronic (>1 year) motor incomplete traumatic SCI were randomized into real rTMS group (n=14) or sham rTMS group (n=14). Real rTMS (20 Hz, a total of 1600 stimuli) or sham r TMS were applied in the motor cortex area of lower extremities during 3 weeks (15 sessions). In addition to rTMS sessions, patients underwent a rehabilitation program including exercises for strengthening, walking and balance.
Study NCT03430999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04372134 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation therapy
Description: A sham-controlled double-blind randomized study was undertaken. 28 patients with chronic (>1 year) motor incomplete traumatic SCI were randomized into real rTMS group (n=14) or sham rTMS group (n=14). Real rTMS (20 Hz, a total of 1600 stimuli) or sham r TMS were applied in the motor cortex area of lower extremities during 3 weeks (15 sessions). In addition to rTMS sessions, patients underwent a rehabilitation program including exercises for strengthening, walking and balance.
Study NCT02878785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: DNA methyltransferase inhibitor
Study NCT02878785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: DNA methyltransferase inhibitor
Study NCT02878785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib
Description: poly ADP ribose polymerase (PARP) inhibitor
Study NCT02878785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: talazoparib
Description: poly ADP ribose polymerase (PARP) inhibitor
Study NCT04430998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc L-Carnosine
Description: Undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 3 minutes, 3 times daily
Study NCT04430998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Undiluted 10 ml of Chlorhexidine mouth rinse, retain for 3 minutes, 3 times daily
Study NCT04430998 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Rinse mouth with 10 ml of water, retain for 3 minutes, 3 times daily
Study NCT04710173 — intervention group
Intervention type: PROCEDURE
Intervention: ECMO
Description: VV-ECMO
Study NCT04545385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48574
Description: subcutaneous infusion
Study NCT04545385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT00915278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04605412
Description: PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal
Study NCT02412995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence 1-2-3
Description: The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
Study NCT02412995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence 1-3-2
Description: The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.